A label-first guide to doxycycline in dogs and cats: extra-label AMDUCA rules, the American Heartworm Society protocol, feline esophageal safety, and openFDA adverse-event reports.

Doxycycline is a second-generation, semi-synthetic tetracycline-class antibiotic that serves as one of the hardest-working and most frequently prescribed antimicrobials in small animal veterinary medicine. Originally derived from oxytetracycline, doxycycline possesses unique chemical properties—most notably high lipophilicity—that allow it to penetrate tissues and cellular membranes far more effectively than first-generation tetracyclines. This allows it to reach therapeutic concentrations in difficult-to-penetrate sites, including the central nervous system, bronchial secretions, prostate gland, and the intracellular environments where many atypical pathogens reside.

In canine and feline practice, doxycycline is the clinical first line for vector-borne rickettsial diseases, a critical convalescent therapy for leptospirosis, and an indispensable adjunctive treatment in the American Heartworm Society (AHS) protocol for canine heartworm disease. However, its widespread clinical utility is accompanied by critical regulatory nuances, high-risk drug-drug interactions, and a species-specific safety risk in cats that can lead to permanent esophageal damage if improper administration techniques are used.

This guide provides a comprehensive, label-first monograph of doxycycline for dogs and cats. We examine the regulatory framework governing its extra-label use under the Animal Medicinal Drug Use Clarification Act (AMDUCA), its pharmacodynamics and clinical indications, its role in heartworm management, its interactions and side effects, and an analysis of the FDA's veterinary adverse-event reports.

The Regulatory Reality: Extra-Label Use and AMDUCA

A regulatory detail almost never addressed on pet health websites is that there is no FDA-approved oral veterinary doxycycline product for systemic administration in dogs and cats in the United States.

While the FDA has approved veterinary-specific doxycycline products for other routes (such as Doxirobe Gel, an injectable periodontal therapeutic gel for dogs), oral tablets and capsules containing doxycycline hyclate or doxycycline monohydrate are human-approved drugs. Therefore, every time a veterinarian prescribes oral doxycycline to a dog or cat, they are practicing extra-label drug use (ELDU).

The Legal Framework of AMDUCA and 21 CFR Part 530

Extra-label drug use is strictly regulated under the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and codified in federal regulations under 21 CFR Part 530. For a veterinarian to legally prescribe oral doxycycline for an animal patient, the following federal criteria must be met:

Valid VCPR: The prescription must be made within a valid Veterinarian-Client-Patient Relationship. The veterinarian must assume responsibility for making clinical judgments, have sufficient knowledge of the patient through recent examination or visits, and be available for follow-up.
No Approved Animal Drug Equivalent: There must be no FDA-approved animal drug that contains the same active ingredient, in the same dosage form and concentration, that is labeled to treat the diagnosed condition—or, if such a drug exists, it must be clinically ineffective for the specific patient. Because there is no oral animal-approved doxycycline, this condition is automatically satisfied.
Health and Welfare Protection: The drug must only be used to treat a diagnosed condition or prevent pain and suffering; using human drugs for production or growth promotion is strictly illegal.
Safety and Residue Precautions: The veterinarian must ensure the drug is safe for the animal, establish appropriate withholding periods for food-producing animals (though doxycycline is rarely used in livestock due to strict residue rules), and provide detailed labeling including instructions and precautions.
No Compounding from Bulk Substances: Under FDA Guidance for Industry (GFI) #256, veterinarians cannot legally compound oral medications from bulk drug substances unless no FDA-approved human or animal drug can serve as the starting material, or there is an urgent clinical need that cannot be met by compounding from the finished commercial product.

Compounded doxycycline liquids are frequently prescribed for small dogs and cats. When doing so, the pharmacist should compound the liquid using FDA-approved human doxycycline tablets or capsules as the starting material rather than bulk active pharmaceutical ingredient (API) powder, unless specific GFI #256 exemptions apply.

Mechanism of Action and Antimicrobial Spectrum

Doxycycline is primarily a bacteriostatic antibiotic, meaning it inhibits bacterial growth and replication rather than directly killing the bacterial cell. It relies on the host's immune system to clear the halted infection.

Cellular Mechanism

Doxycycline exerts its antimicrobial effect by entering the bacterial cell via active transport and passively diffusing across the cell membrane. Once inside, it binds reversibly to the 30S ribosomal subunit of susceptible bacteria. This binding physically blocks the access of aminoacyl-tRNA to the ribosomal acceptor (A) site on the mRNA-ribosome complex. As a result, the addition of new amino acids to the growing peptide chain is prevented, effectively shutting down bacterial protein synthesis.

Antimicrobial Spectrum

Doxycycline possesses a broad spectrum of activity that encompasses Gram-positive, Gram-negative, and atypical pathogens. However, because of widespread acquired resistance among common Gram-positive cocci (Staphylococcus and Streptococcus spp.) and enteric Gram-negative bacilli (Escherichia coli, Klebsiella spp., Proteus spp.), it is rarely selected as a first-line empiric treatment for routine bacterial infections.

Instead, doxycycline is highly valued for its efficacy against:

Rickettsial organisms: Ehrlichia canis, Ehrlichia chaffeensis, Anaplasma phagocytophilum, Anaplasma platys, and Rickettsia rickettsii (the causative agent of Rocky Mountain Spotted Fever).
Spirochetes: Borrelia burgdorferi (Lyme disease) and Leptospira interrogans.
Atypical intracellular bacteria: Mycoplasma spp. (including hemotropic mycoplasmas such as Mycoplasma hemofelis), Chlamydia spp. (Chlamydia felis), and Brucella canis.
Wolbachia endosymbionts: An obligate intracellular bacterium found within the filarial nematode Dirofilaria immitis.

Doxycycline in the Canine Heartworm Treatment Protocol

One of the most common reasons a dog is prescribed a long course of doxycycline is a positive heartworm test. To the layperson, prescribing an antibiotic to treat a parasitic worm infection seems counterintuitive. The clinical justification lies in the symbiotic relationship between Dirofilaria immitis and the intracellular bacterium Wolbachia pipientis.

The Role of Wolbachia in Heartworm Pathology

Wolbachia is an endosymbiont present in all life stages of Dirofilaria immitis. It is crucial for the worm's third- and fourth-stage larval development, adult female fertility, and overall embryogenesis. Furthermore, when adult heartworms die—either naturally or following administration of the adulticide melarsomine dihydrochloride (Immiticide or Diroban)—they release massive quantities of Wolbachia surface proteins (WSP) into the host's circulation.

These bacterial proteins trigger a severe, acute inflammatory cascade in the pulmonary vasculature and lung parenchyma. This immune response contributes significantly to the pulmonary endarteritis, thromboembolism, and parenchymal disease associated with adulticide therapy.

The American Heartworm Society (AHS) Protocol

The American Heartworm Society (AHS) Canine Heartworm Guidelines (most recently updated in November 2024) mandate the administration of doxycycline prior to adulticide therapy. The protocol operates under the following guidelines:

Dose and Frequency: Doxycycline is administered at 10 mg/kg by mouth every 12 hours (BID) for 28 days.
Dose Adjustments: If the dog experiences significant gastrointestinal side effects (vomiting, anorexia, severe nausea), the guidelines support reducing the dose to 5 mg/kg every 12 hours (BID) rather than discontinuing the medication entirely. Keeping the drug in the regimen is vital to achieving the necessary bacterial clearance.
The Treatment Gap (The 30-Day Wait): Following the 28-day course of doxycycline, the AHS protocol requires a 30-day waiting period (a "treatment gap") before administering the first injection of melarsomine. This gap is clinically critical: it allows time for the Wolbachia bacterial load to fully clear, causes the adult heartworms to weaken and degenerate, and allows the pulmonary tissue to recover from the initial larval deaths before the adult worms are eliminated.
Clinical Benefits: Studies compiled by the AHS and the Companion Animal Parasite Council (CAPC) demonstrate that this pre-treatment protocol blocks larval development, reduces the fertility of adult female worms, accelerates the death of adult worms, and significantly reduces the severity of pulmonary thromboembolic complications following adulticide injections.

Prescribing doxycycline without a subsequent adulticide (a practice historically referred to as "slow kill" or "soft kill") is no longer recommended as a primary treatment. The AHS guidelines warn that relying solely on microfilaricides and doxycycline to eliminate adult heartworms can take years, during which time the pulmonary endarteritis and vascular damage continue to progress. For details on why the fast-kill adulticide regimen is preferred over alternative protocols, see the slow kill heartworm treatment analysis.

Feline Esophageal Safety: A Critical Pilling Hazard

In cats, the administration of doxycycline tablets or capsules represents a high-risk safety hazard. If a doxycycline pill becomes lodged in a cat's esophagus, it can cause severe necrotizing esophagitis, which frequently heals by forming a permanent, life-threatening esophageal stricture.

Pathophysiology of Doxycycline-Induced Esophagitis

Feline esophageal physiology differs significantly from that of dogs. In cats, the distal third of the esophagus is composed entirely of smooth muscle (compared to skeletal muscle throughout the canine esophagus), which exhibits slower peristaltic clearance. Furthermore, dry pills are highly likely to remain lodged in the feline esophagus for extended periods.

Doxycycline hyclate is highly acidic; when dissolved in a small amount of residual moisture in the esophagus, it creates a local environment with a pH of approximately 2.0 to 3.0. This concentrated acid causes chemical burns to the mucosal lining.

A landmark case series published in peer-reviewed literature (see PMC10911547) evaluated cats that developed esophageal strictures following oral drug administration. Doxycycline hyclate tablets and capsules were identified as the single most common cause of drug-associated esophageal injury. Symptoms of esophageal stricture include:

Hypersalivation (drooling)
Regurgitation of undigested food immediately after eating
Odynophagia (painful swallowing)
Progressive weight loss
Coughing or dyspnea secondary to aspiration pneumonia

Esophageal strictures are difficult and expensive to treat. They require multiple rounds of endoscopic balloon dilation under general anesthesia, and many cats never regain normal esophageal function.

Esophageal Safety Protocols

To eliminate the risk of esophageal strictures in cats, veterinarians and owners must adhere to one of the following administration protocols:

Administration Method	Clinical Protocol
Water Flush (Required for Pills)	If oral tablets or capsules must be used, never dry-pill a cat. Immediately follow the administration of the pill with at least 6 mL of water delivered via an oral syringe to flush the pill into the stomach.
Food Chaser	Follow the pill immediately by feeding the cat a small amount of wet canned food or a highly palatable liquid treat to facilitate swallowing.
Liquid Formulations	Utilize a compounded liquid suspension (such as doxycycline monohydrate) instead of solid tablets or capsules. Doxycycline monohydrate is chemically less acidic than doxycycline hyclate and carries a lower risk of mucosal damage.
Compounded Chews	Use soft, moist compounded veterinary treats that disintegrate quickly and pass easily through the esophagus.

Clinical Indications in Dogs and Cats

Beyond heartworm adjunctive therapy, doxycycline is a first-line choice for several common veterinary diseases:

1. Tick-Borne Rickettsial Diseases

Doxycycline is the gold standard for treating tick-borne infections in dogs, including:

Ehrlichiosis (Ehrlichia canis): Characterized by thrombocytopenia, fever, lethargy, and splenomegaly. Dosed at 5–10 mg/kg PO or IV every 12–24 hours for 28 days.
Anaplasmosis (Anaplasma phagocytophilum, Anaplasma platys): Causes joint pain, thrombocytopenia, and fever. Treated for 14–21 days.
Rocky Mountain Spotted Fever (Rickettsia rickettsii): A severe vasculitic disease requiring rapid treatment.
Lyme Borreliosis (Borrelia burgdorferi): Doxycycline is administered at 10 mg/kg PO every 12–24 hours for 28 days. It treats active clinical signs (joint lameness, lymphadenopathy) but does not completely eradicate the spirochete from the host tissue.

In responsive cases of acute rickettsial disease, clinical signs (such as fever and lethargy) typically resolve dramatically within 24 to 48 hours of starting doxycycline. For a comprehensive overview of tick-borne diagnostics and staging, refer to our guide on tick borne diseases in dogs.

2. Convalescent Leptospirosis Therapy

In dogs diagnosed with leptospirosis, penicillin-class antibiotics (like ampicillin) are used initially in the acute phase to halt leptospiremia and systemic infection. However, penicillins fail to clear the bacteria from the renal tubules, leaving the dog as a chronic renal carrier that sheds infectious leptospires in its urine, posing a zoonotic risk to humans.

Once the dog is stable and no longer vomiting, doxycycline is administered at 5 mg/kg PO every 12 hours for 14 days to eliminate the renal carrier state. For clinical management of the acute renal phase, see our guide on leptospirosis in dogs.

3. Respiratory Tract Infections

Doxycycline is highly effective against major pathogens involved in the Canine Infectious Respiratory Disease Complex (CIRDC, or "kennel cough") and feline upper respiratory tract infections, particularly:

Bordetella bronchiseptica
Mycoplasma spp.
Chlamydia felis (in cats presenting with severe conjunctivitis and rhinitis)

4. Atypical and Intracellular Infections

Hemotropic Mycoplasmosis: In cats, Mycoplasma hemofelis infects red blood cells, causing life-threatening feline infectious anemia. Doxycycline (10 mg/kg PO daily for 14–21 days) is the standard treatment to reduce the parasitemia, often paired with prednisolone to suppress immune-mediated destruction of RBCs.
Toxoplasmosis (Toxoplasma gondii): Doxycycline is sometimes used as an alternative or adjunctive therapy in dogs and cats showing neurological or ocular signs of toxoplasmosis.

Adverse Effects, Contraindications, and Monitoring

While doxycycline is generally well-tolerated, its chemical and pharmacological properties contribute to several common side effects.

Gastrointestinal Side Effects

Gastrointestinal upset is the most common side effect in both dogs and cats. Signs include:

Vomiting (emesis)
Diarrhea or loose stools
Nausea and hypersalivation
Anorexia or decreased appetite

Unlike older tetracyclines, doxycycline is highly lipophilic and its absorption is only minimally decreased by the presence of food. Therefore, veterinarians recommend administering doxycycline with a small meal to reduce direct gastric irritation, provided the food does not contain high levels of divalent cations (see drug interactions below).

Hepatotoxicity and ALT Elevation

Doxycycline is metabolized primarily by the liver and excreted into the feces via the biliary tract (exhibiting minimal renal elimination, which makes it safer in renal failure than other tetracyclines). However, it can cause transient, mild-to-moderate elevations in liver enzymes, particularly alanine aminotransferase (ALT) and alkaline phosphatase (ALP).

In patients with pre-existing hepatic impairment, or during prolonged courses (such as the 28-day AHS heartworm protocol), baseline and mid-point liver panels are recommended. Dose reductions or hepatoprotective supplements (such as S-adenosylmethionine or silybin) may be warranted if ALT levels exceed three times the upper reference limit.

Teeth Staining in Developing Animals

Tetracyclines bind to calcium orthophosphate, forming a stable tetracycline-calcium orthophosphate complex that deposits in active sites of calcification. When administered to pregnant animals during the last half of gestation, or to young puppies and kittens during the first 8 weeks of life, it can cause permanent yellow-brown discoloration of the deciduous or permanent teeth and slow bone development.

Because doxycycline has a lower affinity for calcium than older tetracyclines (like oxytetracycline), the risk of teeth staining is lower. However, it should still be avoided in pregnant, lactating, or very young animals unless no viable antibiotic alternative exists.

Photosensitivity

Tetracyclines can act as phototoxic agents. Dogs and cats receiving doxycycline may experience increased sensitivity to ultraviolet light, leading to erythema, dermatitis, or sunburn on sparsely haired or non-pigmented areas (such as the nose, eyelids, and ears). Animals on doxycycline should be kept out of direct, intense sunlight.

High-Risk Drug Interactions and Chelation Chemistry

Doxycycline is subject to several clinically significant drug interactions that can cause treatment failure or severe toxicity.

1. Cation Chelation (The Antacid and Dairy Trap)

Like all tetracyclines, doxycycline chelates divalent and trivalent cations, including calcium (Ca²⁺), magnesium (Mg²⁺), aluminum (Al³⁺), iron (Fe²⁺/³⁺), and bismuth (Bi³⁺).

When doxycycline is administered orally alongside substances containing these cations, it binds to them in the gastrointestinal tract, forming an insoluble complex that cannot be absorbed across the intestinal mucosa. This drastically reduces the bioavailability of the antibiotic, leading to sub-therapeutic tissue levels and treatment failure.

To prevent chelation-induced treatment failure:

Avoid Dairy: Do not administer doxycycline pills wrapped in cheese, butter, cream cheese, or yogurt.
Separate Antacids and Supplements: Administer antacids (such as calcium carbonate, magnesium hydroxide, or aluminum hydroxide), sucralfate, bismuth subsalicylate, oral iron supplements, and multivitamin-mineral supplements at least 2 hours before or 2 hours after the doxycycline dose.

2. Anticoagulant Interactions (Warfarin)

Doxycycline can suppress the activity of intestinal microflora that produce Vitamin K, a cofactor essential for the synthesis of coagulation factors II, VII, IX, and X. In patients receiving oral anticoagulants like warfarin, co-administration of doxycycline can potentiate the anticoagulant effect, leading to an increased risk of hemorrhage. Prothrombin time (PT) or mucosal bleeding times should be monitored closely in these patients.

3. Digoxin Toxicity Risk

In a small percentage of canine patients, a significant portion of administered digoxin is metabolized by intestinal bacteria (specifically Eubacterium lentum) before absorption. By eliminating these gut bacteria, doxycycline can increase the systemic bioavailability of digoxin, raising serum concentrations and increasing the risk of digoxin toxicity (characterized by cardiac arrhythmias, severe vomiting, and depression). Digoxin levels must be monitored when doxycycline is added to the regimen.

4. Interactions with Hepatic Enzyme Inducers

Drugs that induce hepatic microsomal enzymes, such as phenobarbital or phenytoin, can accelerate the metabolism of doxycycline in the liver. This shortens the half-life of the antibiotic, which may require a dose increase or a shift to a 12-hour dosing interval to maintain therapeutic levels.

5. Interference with Bactericidal Antibiotics

Because doxycycline is a bacteriostatic drug that halts bacterial growth, it should not be administered concurrently with bactericidal antibiotics that require active cell division to kill bacteria, such as penicillins (e.g., ampicillin, amoxicillin, Clavamox) or cephalosporins (e.g., cephalexin, Cefpodoxime).

For example, when managing a complex skin infection or severe wound, using doxycycline and amoxicillin simultaneously can result in antimicrobial antagonism, where the doxycycline prevents the bacteria from dividing, making the amoxicillin ineffective. For more on selecting and timing antibiotics, see the antimicrobial stewardship program guide.

Analysis of FDA openFDA Adverse-Event Data

To understand the real-world safety profile of doxycycline in clinical practice, we analyzed the FDA Center for Veterinary Medicine's animal drug adverse-event records, accessed through the openFDA database (analysis run date: 2026-07-05).

The search identified 4,320 unique reports where doxycycline was recorded as an active ingredient. The species breakdown shows a strong canine dominance:

Dogs: 3,870 reports (89.6%)
Cats: 251 reports (5.8%)
Other (Horses, Humans, Unknown): 199 reports (4.6%)

Top 10 Reported Reaction Terms

The table below lists the ten most frequent reaction terms associated with doxycycline in the database:

Position	Reaction Term	Report Count	Clinical Context and Interpretation
1	Lack of efficacy (endoparasite) - heartworm	1,194	Reflected use as Wolbachia adjunct in heartworm treatment; reported when heartworm treatment fails, not antibiotic failure.
2	Vomiting	602	Direct gastric mucosal irritation; the most common true drug side effect.
3	Lethargy	468	Systemic sign; heavily confounded by severe underlying infections (rickettsia, heartworm).
4	Other abnormal test result NOS	357	Diagnostic marker; often reflects laboratory monitoring during chronic illness.
5	Death by euthanasia	330	Outcome; represents humane endpoints in severe or terminal disease states.
6	Anorexia	313	Decreased appetite; common secondary effect of drug-induced nausea or active infection.
7	Elevated alanine aminotransferase (ALT)	284	Direct hepatic signal; reflects hepatic metabolism and drug-induced enzyme elevation.
8	Diarrhoea	269	Intestinal mucosal irritation and disruption of normal gut microflora.
9	Lack of efficacy - NOS	264	General efficacy failure; includes off-label use cases and resistant bacterial strains.
10	Death	241	Outcome; mortality associated with advanced vector-borne infections or heartworm disease.

Interpreting the openFDA Safety Signals

A critical analysis of these reported reactions reveals important clinical lessons:

The Heartworm Reporting Confound: The leading reported reaction is "Lack of efficacy (endoparasite) - heartworm" (1,194 reports). This does not indicate that doxycycline failed as an antibiotic. Instead, it reflects its role as an adjunctive treatment in the canine heartworm protocol. When a dog undergoing heartworm treatment fails to clear microfilariae, develops adulticide complications, or does not convert to heartworm-negative status, doxycycline is listed on the adverse event report because it was part of the multi-drug regimen.
Gastrointestinal and Hepatic Profile: The high frequency of vomiting (602), anorexia (313), elevated ALT (284), and diarrhea (269) directly corroborates the drug's labeled safety profile. It reinforces the clinical need to administer the drug with food, monitor liver panels during long courses, and watch for liver enzyme elevations.
Mortality and Polypharmacy: Across the 4,320 reports, 586 reports carried a fatal outcome (323 euthanized, 264 died). In the veterinary pharmacovigilance database, these deaths are almost exclusively associated with dogs and cats presenting with advanced, life-threatening diseases (such as caval syndrome in heartworm disease, severe chronic rickettsial pancytopenia, or advanced infectious respiratory distress). These cases also typically involve multiple concurrent medications. These report-level counts represent passive surveillance data and must not be interpreted as a causal mortality rate for doxycycline itself.

Frequently Asked Questions

Is doxycycline safe for cats, and why does my vet want me to give water with the pill?

Doxycycline is highly effective in cats but requires strict administration precautions. Dry pills can easily get stuck in a cat’s esophagus, where the highly acidic drug can cause severe chemical burns and permanent esophageal strictures. To prevent this, always follow a doxycycline pill with at least 6 mL of water via a syringe, or feed your cat immediately after pilling. Alternatively, ask your veterinarian for a liquid suspension.

Can doxycycline be given with food, antacids, or dairy?

Doxycycline should be given with a small, non-dairy meal to reduce stomach upset. However, it should never be given with dairy products (milk, cheese, yogurt) or antacids, iron supplements, and multivitamins. These products contain calcium, magnesium, aluminum, or iron, which bind to the doxycycline in the stomach and prevent it from being absorbed, making the antibiotic ineffective. Separate these interactants by at least 2 hours.

Why was doxycycline prescribed for heartworm when it is an antibiotic?

Doxycycline does not kill the heartworms directly. Instead, it kills Wolbachia, a symbiotic bacterium that lives inside the heartworms and is essential for their survival and reproduction. Killing Wolbachia weakens the adult worms, blocks larval development, and reduces the severe inflammation and blood-clotting risks that occur in the lungs when the adult worms die during adulticide treatment.

How long does a dog or cat take doxycycline, and what happens if a dose is missed?

For tick-borne diseases, the course is typically 14 to 28 days. For heartworm treatment, the American Heartworm Society protocol requires exactly 28 days of twice-daily dosing. If you miss a dose, administer it as soon as you remember. If it is close to the next scheduled dose, skip the missed dose and resume the normal schedule—never double the dose. Inform your veterinarian if multiple doses are missed, as this can lead to treatment failure.

Sources

DailyMed. Doxycycline Hyclate (systemic human tablets and capsules) prescribing information. https://dailymed.nlm.nih.gov/dailymed/lookup/urldemo?setid=e2724cf6-e069-42b7-8480-1fe9de2cb30f
FDA Animal Drugs @ FDA. Doxirobe Gel (doxycycline clinical periodontal gel, NADA 141-191) approval and Freedom of Information summary. https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/858
American Heartworm Society. Current Canine Guidelines for the Diagnosis, Prevention, and Management of Heartworm Infection in Dogs (November 2024). https://d3ft8sckhnqim2.cloudfront.net/images/AHS_Canine_Guidelinesweb22NOV2024.pdf
Companion Animal Parasite Council (CAPC). Heartworm Guidelines: Canine and Feline. https://capcvet.org/guidelines/heartworm/
PubMed Central (PMC). Feline esophageal strictures and drug-associated esophagitis (PMC10911547). https://pmc.ncbi.nlm.nih.gov/articles/PMC10911547/
Merck Veterinary Manual. Tetracyclines: Pharmacology and Clinical Use. https://www.merckvetmanual.com/pharmacology/antimicrobial-agents/tetracyclines
FDA CVM. Animal Medicinal Drug Use Clarification Act (AMDUCA) and Extra-Label Drug Use (ELDU) regulations. https://www.fda.gov/animal-veterinary/guidance-regulations/animal-medicinal-drug-use-clarification-act-1994-amduca
Veterinary Information Network (VIN) / Veterinary Partner. Doxycycline Monograph. https://veterinarypartner.vin.com/default.aspx?pid=19239&catId=102894&id=4951421
FDA Center for Veterinary Medicine. openFDA Animal & Veterinary Adverse Event API (report-level adverse-event records, 1987–2026; analysis run date 2026-07-05). https://open.fda.gov/apis/animalandveterinary/

Doxycycline for Dogs and Cats: Heartworm, Tick-Borne Disease, and Label Reality